Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Paraneoplastic Leukemoid Reaction Associated with Increased Levels of and Tumor Overexpression of Receptors for G-CSF, GM-CSF, and IL-6: A Clinico-Pathological-Molecular Study

Alejandro Recio Boiles, MD, Eric M. Lander, MD, George S. Watts, PhD, Steffan T. Nawrocki, PhD, Andrew M. Yeager, MD

Blood (2018) 132 (Supplement 1): 4945.

https://doi.org/10.1182/blood-2018-99-115736

Published: 2018

Journal Articles

Safety and Efficacy of Plerixafor on a Convenient Dose Schedule to Facilitate Outpatient Hematopoietic Stem Cell Collection for Autologous Hematopoietic Transplantation

Christopher Chen, MD MBA, Andrew M. Yeager, MD, Faiz Anwer, MD, Ali McBride, PharmD, MS, Keri R Maher, DO, Christopher Campen, PharmD

Blood (2016) 128 (22): 5736.

https://doi.org/10.1182/blood.V128.22.5736.5736

Published: 2016

Journal Articles

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

Jeffrey E. Lancet, Jorge E. Cortes, Donna E. Hogge, Martin S. Tallman, Tibor J. Kovacsovics, Lloyd E. Damon, Rami Komrokji, Scott R. Solomon, Jonathan E. Kolitz, Maureen Cooper, Andrew M. Yeager, Arthur C. Louie, Eric J. Feldman

Blood (2014) 123 (21): 3239–3246.

https://doi.org/10.1182/blood-2013-12-540971

Published: 2014

Includes: Supplemental data

Journal Articles

Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors

Blood (2010) 116 (21): 1292.

https://doi.org/10.1182/blood.V116.21.1292.1292

Published: 2010

Journal Articles

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Blood (2010) 116 (21): 3450.

https://doi.org/10.1182/blood.V116.21.3450.3450

Published: 2010

Journal Articles

Effective Primary Mobilization of Autologous Peripheral Blood Stem Cells with Granulocyte Colony-Stimulating Factor and Plerixafor in Lenalidomide-Treated Patients with Multiple Myeloma

Faiz Anwer, MD, Myke R Green, BS, PharmD, BCOP, Andrew M. Yeager, MD

Blood (2010) 116 (21): 2254.

https://doi.org/10.1182/blood.V116.21.2254.2254

Published: 2010

Journal Articles

Pentostatin and Alemtuzumab: An Immunosuppressive Nonmyeloablative Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).

Faiz Anwer, MD, Michael P. Carroll, MD, Myke R. Green, PharmD, Lee Cranmer, MD, PhD, Leona Downey, MD, Linda Garland, MD, Katayoun Moini, MHS, PA-C, Daniel O. Persky, MD, Rachel Swart, MD, PhD, Andrew M. Yeager, MD

Blood (2009) 114 (22): 4312.

https://doi.org/10.1182/blood.V114.22.4312.4312

Published: 2009

Journal Articles

Effects of Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) and Plerixafor On Lymphocyte Subsets in Autologous Peripheral Blood Stem Cell (PBSC) Apheresis Products.

Emad Elquza, MD, Catherine Spier, MD, Roger Fiederlein, MT, David Salamon, SBB, Andrew M. Yeager, MD

Blood (2009) 114 (22): 2145.

https://doi.org/10.1182/blood.V114.22.2145.2145

Published: 2009

Journal Articles

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

Blood (2008) 112 (11): 149.

https://doi.org/10.1182/blood.V112.11.149.149

Published: 2008

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

Blood (2008) 112 (11): 2162.

https://doi.org/10.1182/blood.V112.11.2162.2162

Published: 2008

Journal Articles

Treatment of Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL) or Hodgkin’s Disease (HD) with High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (HSCT) Using a Novel Mitoxantrone-Containing Preparative Regimen.

Leslie Andritsos, MD, Wendy Suhre, Mark Nahirny, Ellen Chase, Michael Carroll, M.D., Jennifer Christian, Thomas P. Miller, MD, Andrew M. Yeager, M.D.

Blood (2006) 108 (11): 5264.

https://doi.org/10.1182/blood.V108.11.5264.5264

Published: 2006

Journal Articles

Bortezomib Induces Rapid Upregulation of Topoisomerase IIα and Demonstrates Schedule-Dependent Synergistic Cytotoxicity with Anthracyclines and Etoposide in Acute Myeloid Leukemia and Myeloma Cell Lines.

Michael P. Carroll, MD, Olin Feuerbacher, Andrew M. Yeager, MD, Terry H. Landowski, PhD

Blood (2005) 106 (11): 2478.

https://doi.org/10.1182/blood.V106.11.2478.2478

Published: 2005

Journal Articles

Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience.

Tom V. Adamkiewicz, MD, Ann Haight, MD, Melissa A. Mazur, MD, K. Scott Baker, MD, Paul Szabolcs, MD, Amos Kedar, MD, K.Y. Chiang, MD, Lakshmanan Krishnamurti, MD, John E. Wagner, MD, John R. Wingard, MD, Andrew M. Yeager, MD

Blood (2005) 106 (11): 2044.

https://doi.org/10.1182/blood.V106.11.2044.2044

Published: 2005

Journal Articles

Outpatient High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Is Associated with a Low Infection Safety Profile.

Mounzer E. Agha, M.D., Andrew M. Yeager, M.D., Carol Evans, M.D., Nikol Borkowski, P.A.-C., Anne Marie Scekeres, R.N., Sarah Miller, P.A.-C., Cheryl Tompkins, C.R.N.P., Rowena Schwartz, Pharm.D., Albert D. Donnenberg, Ph.D., Jeffrey Shogan, M.D.

Blood (2004) 104 (11): 5070.

https://doi.org/10.1182/blood.V104.11.5070.5070

Published: 2004

Journal Articles

Infection Is the Major Cause of Mortality after Nonmyeloablative Unrelated Bone Marrow Transplantation with Alemtuzumab, Fludarabine and Melphalan.

Michael P. Carroll, M.D., Diane BuchBarker, M.D., Rowena Schwartz, Pharm.D., Mounzer E. Agha, M.D., Cheryl Tompkins, C.R.N.P., Kristen Baileys, C.R.N.P., Kathleen O’Connell, R.N., Albert D. Donnenberg, Ph.D., Andrew M. Yeager, M.D.

Blood (2004) 104 (11): 5165.

https://doi.org/10.1182/blood.V104.11.5165.5165

Published: 2004

Journal Articles

Intensive Immunosuppression Plus T-Cell Depleted Autologous Peripheral Blood Stem Cell Transplantation for Systemic Sclerosis.

Diane BuchBarker, M.D., Albert D. Donnenberg, Ph.D., Thomas A. Medsger, M.D., Michael P. Carroll, M.D., Deborah L. Griffin, B.A., Carol Blair, R.N., Darrell Lis, R.N., M.S.N., Andrew M. Yeager, M.D.

Blood (2004) 104 (11): 5205.

https://doi.org/10.1182/blood.V104.11.5205.5205

Published: 2004

Journal Articles

Analysis of T-Cell Repertoire before and 21 Days after Autologous Peripheral Blood Stem Cell Transplantation for Systemic Sclerosis.

Albert D. Donnenberg, PhD, Vera S. Donnenberg, PhD, Thomas A. Medsger, MD, Diane M. BuchBarker, MD, Dawn M. Betters, Andrew M. Yeager, MD

Blood (2004) 104 (11): 1648.

https://doi.org/10.1182/blood.V104.11.1648.1648

Published: 2004

Journal Articles

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors

Richard A. Nash, Joseph H. Antin, Chatchada Karanes, Joseph W. Fay, Belinda R. Avalos, Andrew M. Yeager, Donna Przepiorka, Stella Davies, Finn B. Petersen, Pamela Bartels, Donald Buell, William Fitzsimmons, Claudio Anasetti, Rainer Storb, Voravit Ratanatharathorn

Blood (2000) 96 (6): 2062–2068.

https://doi.org/10.1182/blood.V96.6.2062

Published: 2000

Journal Articles

Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report

Blood (2000) 95 (6): 1918–1924.

https://doi.org/10.1182/blood.V95.6.1918

Published: 2000

Journal Articles

Lymphoid Reconstitution After Autologous PBSC Transplantation With FACS-Sorted CD34 + Hematopoietic Progenitors

Catherine Bomberger, Meeta Singh-Jairam, Glenn Rodey, Anastasia Guerriero, Andrew M. Yeager, William H. Fleming, H. Kent Holland, Edmund K. Waller

Blood (1998) 91 (7): 2588–2600.

https://doi.org/10.1182/blood.V91.7.2588

Published: 1998

NARROW

Paraneoplastic Leukemoid Reaction Associated with Increased Levels of and Tumor Overexpression of Receptors for G-CSF, GM-CSF, and IL-6: A Clinico-Pathological-Molecular Study

Safety and Efficacy of Plerixafor on a Convenient Dose Schedule to Facilitate Outpatient Hematopoietic Stem Cell Collection for Autologous Hematopoietic Transplantation

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Effective Primary Mobilization of Autologous Peripheral Blood Stem Cells with Granulocyte Colony-Stimulating Factor and Plerixafor in Lenalidomide-Treated Patients with Multiple Myeloma

Pentostatin and Alemtuzumab: An Immunosuppressive Nonmyeloablative Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).

Effects of Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) and Plerixafor On Lymphocyte Subsets in Autologous Peripheral Blood Stem Cell (PBSC) Apheresis Products.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

Treatment of Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL) or Hodgkin’s Disease (HD) with High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (HSCT) Using a Novel Mitoxantrone-Containing Preparative Regimen.

Bortezomib Induces Rapid Upregulation of Topoisomerase IIα and Demonstrates Schedule-Dependent Synergistic Cytotoxicity with Anthracyclines and Etoposide in Acute Myeloid Leukemia and Myeloma Cell Lines.

Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience.

Outpatient High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Is Associated with a Low Infection Safety Profile.

Infection Is the Major Cause of Mortality after Nonmyeloablative Unrelated Bone Marrow Transplantation with Alemtuzumab, Fludarabine and Melphalan.

Intensive Immunosuppression Plus T-Cell Depleted Autologous Peripheral Blood Stem Cell Transplantation for Systemic Sclerosis.

Analysis of T-Cell Repertoire before and 21 Days after Autologous Peripheral Blood Stem Cell Transplantation for Systemic Sclerosis.

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors

Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report

Lymphoid Reconstitution After Autologous PBSC Transplantation With FACS-Sorted CD34 + Hematopoietic Progenitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only